The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer’s disease: a systematic review and meta-analysis of randomized controlled trials

45Citations
Citations of this article
96Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Alzheimer’s disease (AD) is a worldwide public health problem and is difficult to cure. Drugs aimed at slowing the progression of the disease have been developed, with the Food and Drug Administration (FDA) granting accelerated approval for aducanumab on June 21, 2021 and a new accelerated approval for lecanemab on January 22, 2023. We performed this systematic review and meta-analysis to assess the efficacy and safety of FDA-approved anti-amyloid-β (anti-Aβ) monoclonal antibodies (mabs) for the treatment of AD. Method: PubMed, Embase, and Cochrane Library were systematically searched to identify relevant studies published before May 2023. Efficacy outcomes included Aβ, neuroimaging, and biomarker outcomes. Safety outcomes included amyloid-related imaging abnormalities with edema or effusions (ARIA-E) and ARIA with cerebral microhemorrhages, cerebral macrohemorrhages, or superficial siderosis (ARIA-H). Review Manager 5.4 software was used to assess the data. The standard mean differences (SMDs) or odds ratio (OR) with 95% confidence interval (95% CI) were analyzed and calculated with a random effect model or a fixed effect model. Result: Overall, 4471 patients from 6 randomized controlled trials (RCTs), with 2190 patients in the treatment group and 2281 patients in the placebo group meeting the inclusion criteria. FDA-approved anti-Aβ mabs showed statistically significant improvements in clinical outcomes, including CDR-SB (P = 0.01), ADCS-ADL-MCI (P = 0.00003), ADCOMS (P < 0.00001), ADAS-Cog (P < 0.00001). Moreover, FDA-approved anti-Aβ mabs increased cerebrospinal fluid (CSF) Aβ1-42 (P = 0.002) and plasma Aβ42/40 ratios (P = 0.0008). They also decreased CSF P-Tau (P < 0.00001), CSF T-Tau (P < 0.00001), and plasma p-tau181 (P < 0.00001). FDA-approved anti-Aβ mabs perform neuroimaging changes in amyloid Positron Emission Tomography Standardized Uptake Value ratio (PET SUVr) (P < 0.00001). However, compared with placebo, FDA-approved anti-Aβ mabs had higher risk of ARIA-E (P < 0.00001) and ARIA-H (P < 0001). Conclusion: FDA-approved anti-Aβ mabs have a role in slowing disease progression in patients with AD, at the cost of an increased probability of side effects.

References Powered by Scopus

The PRISMA 2020 statement: An updated guideline for reporting systematic reviews

45803Citations
N/AReaders
Get full text

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease

6571Citations
N/AReaders
Get full text

The amyloid hypothesis of Alzheimer's disease at 25 years

4354Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Type 2 diabetes mellitus/obesity drugs: A neurodegenerative disorders savior or a bridge too far?

7Citations
N/AReaders
Get full text

Insights on the Use of Transgenic Mice Models in Alzheimer’s Disease Research

7Citations
N/AReaders
Get full text

Biological markers of Alzheimer's disease in cerebrospinal fluid: clinical and laboratory comparisons

5Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Wu, W., Ji, Y., Wang, Z., Wu, X., Li, J., Gu, F., … Wang, Z. (2023, December 1). The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer’s disease: a systematic review and meta-analysis of randomized controlled trials. European Journal of Medical Research. BioMed Central Ltd. https://doi.org/10.1186/s40001-023-01512-w

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 15

58%

Professor / Associate Prof. 5

19%

Researcher 5

19%

Lecturer / Post doc 1

4%

Readers' Discipline

Tooltip

Medicine and Dentistry 8

32%

Neuroscience 7

28%

Agricultural and Biological Sciences 5

20%

Biochemistry, Genetics and Molecular Bi... 5

20%

Article Metrics

Tooltip
Mentions
Blog Mentions: 1
News Mentions: 3

Save time finding and organizing research with Mendeley

Sign up for free